30 results on '"Cary, Clint"'
Search Results
2. Management of relapsed stage I nonseminomatous germ-cell tumor with retroperitoneal only relapse.
3. Post chemotherapy retroperitoneal lymph node dissection (PC-RPLND) for metastatic pure seminoma.
4. Primary Retroperitoneal Lymph Node Dissection for Stage II Seminoma: Is Surgery the New Path Forward?
5. Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy
6. Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor—N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary?
7. Oncologic outcomes of primary retroperitoneal lymph node dissection (RPLND) for stage II seminoma: Indiana University experience.
8. Adjuvant chemotherapy with CAV/IE for malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): An institutional analysis from Indiana University.
9. Surveillance after complete response in patients with metastatic non-seminomatous germ-cell tumor (NSGCT).
10. Late relapse of germ cell tumors: Detection and treatment outcomes.
11. Comprehensive genomic profiling (CGP) in patients with relapsed/refractory germ cell tumors (GCT).
12. SEMS trial: Result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma.
13. Prediction model for brain metastasis (BM) in patients with metastatic germ-cell tumors (mGCT) accounting for size of pulmonary metastases.
14. Model to predict brain metastasis (BM) in patients with metastatic germ-cell tumors (mGCT).
15. Comprehensive genomic profiling (CGP) in patients with relapsed/refractory germ cell tumors (GCT).
16. Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)- eligible cohort of HCRN GU14-188.
17. Prognostic Value of Teratoma in Primary Tumor and Postchemotherapy Retroperitoneal Lymph Node Dissection Specimens in Patients With Metastatic Germ Cell Tumor
18. Expression of circulating miR375 and miR371 to differentiate teratoma and viable germ cell tumor in patients with post-chemotherapy residual disease.
19. Prognostic value of serum tumor marker (STM) rate of decline during high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT) for relapsed germ-cell tumors (rGCT).
20. Risk of Bleomycin-Related Pulmonary Toxicities and Operative Morbidity After Postchemotherapy Retroperitoneal Lymph Node Dissection in Patients With Good-Risk Germ Cell Tumors
21. Adverse health outcomes (AHO) after modern cisplatin-based chemotherapy (CHEM) compared to surgery-only: A study of 503 testicular cancer survivors (TCS).
22. Retroperitoneal cancer viability after postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in good risk germ cell tumors (GCTs).
23. A pilot study to assess the accuracy of “intuition” in analyzing post chemotherapy (chemo) residual retroperitoneal (RP) masses in patients (pts) with non seminomatous germ cell tumor (NSCGCT).
24. The prognostic value of teratoma in the primary tumor and postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) specimens in patients with germ cell tumors (GCTs).
25. Management of pure metastatic teratoma in chemotherapy naïve testis cancer patients.
26. Development of a novel algorithm to identify staging and lines of therapy for bladder cancer.
27. Three-dimensional lymph node volume and craniocaudal lymph node length as an independent risk factor for recurrence or presence of micrometastatis in clinical stage I non-seminomatous germ cell tumors: A retrospective study.
28. Does adjuvant treatment affect survival in patients with positive lymph nodes at radical prostatectomy?
29. Outcomes after post-operative radiation therapy.
30. Disparities in prostate cancer treatment associated with population density of the county of residence.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.